Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing ficerafusp alfa, reporting 66,387,197 shares of common stock outstanding as of November 3, 2026. The company continues to incur significant financial losses and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Bicara Therapeutics reported Q3 2026 financial results, ending the period with $442.3 million in cash and marketable securities. The company achieved substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer, with topline interim results expected in mid-2027. Management expects current cash reserves to fund operations into the first half of 2029.
Term
Q3 2026
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
“Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer